INTRODUCTION
============

Cigarette smoking continues to be the leading preventable cause of death in most countries.[@B1] It is associated with high morbidity rates and generates significantly high financial costs for the health care system.[@B2] Promoting smoking cessation is an important strategy to reduce the morbidity and mortality associated with smoking-related diseases. In Brazil, smoking is also a major public health problem, although there is a major trend toward a decrease in the proportion of smokers. Recent data show that the prevalence of smoking among individuals ≥ 18 years of age decreased from 15.6% in 2006 to 10.8% in 2015 (p \< 0.05), corresponding to a 30.7% reduction.[@B3]

The inverse relationship between body weight and smoking is well recognized.[@B4] ^-^ [@B6] Smokers typically have a lower body weight than do nonsmokers.[@B7] ^,^ [@B8] Reduced food intake in smokers has been attributed to various mechanisms[@B7] ^,^ [@B9] ^,^ [@B10]: increased stimulation of the adrenergic system; lipolysis and thermogenesis secondary to an increased basal metabolic rate; increased energy expenditure; and nicotine-induced appetite suppression. There is also evidence that some additives employed in the industrial production of the cigarettes are appetite suppressants, such as tartaric acid and 2-acetylpyridine.[@B11] Conversely, smoking cessation is associated with weight gain,[@B10] and former smokers usually weigh more than do current smokers and never smokers.[@B5] ^,^ [@B12] ^-^ [@B14] When an individual quits smoking, the aforementioned mechanisms cease to operate, leading to an increase in body weight. A low socioeconomic status (SES) is also a contributing factor for weight gain. Currently, most smokers belong to a lower SES, engage in less physical activity, and have a high-calorie/high-fat diet. The increase in caloric intake is probably responsible for the greater proportional weight gain seen during the first 3 months after smoking cessation.[@B10] In addition, former smokers seek oral rewards through the consumption of foods with high sugar and fat content. There is also a rapid recovery of the senses of smell and taste, which encourages food intake.[@B11]

There is evidence that a considerable proportion of smokers gain weight when they quit smoking.[@B8] ^,^ [@B15] ^-^ [@B17] Approximately 50% of women and 26% of men state that their main concern in quitting smoking is weight gain, which is also a major risk factor for relapse.[@B18] The significant proportion of former smokers who maintain their original weight or show no more than 5% variation in relation to their baseline weight is not usually emphasized during the counseling of smokers who are about to initiate an attempt to stop smoking.

The aim of this study was to assess weight changes during the smoking cessation process and to identify the factors involved in such changes. We had a special interest in the subgroup of patients that maintained their weight or showed a variation of no more than 5% in relation to their baseline weight.[@B19] We also calculated the number needed to harm (NNH), which, for the purposes of the present study, was the number of patients required in order to identify one patient with a clinically relevant weight gain in relation to the baseline weight among the smokers who succeeded in quitting smoking.

METHODS
=======

This was a prospective cohort study of smokers who sought treatment at the Outpatient Smoking Cessation Clinic of Hospital São Lucas da Pontifícia Universidade Católica do Rio Grande do Sul (HSL-PUCRS, São Lucas Hospital of the Pontifical Catholic University of Rio Grande do Sul), in the city of Porto Alegre, Brazil. The screening period was from June 2010 to June 2016.

The inclusion criteria were being a current smoker, having a ≥ 10 pack-year smoking history, being motivated to quit smoking, and not having been under treatment for smoking cessation in the last 6 months. The exclusion criteria were having a severe clinical or psychiatric illness, including self-reported alcohol or illicit drug abuse, as well as being illiterate, being pregnant, and breastfeeding.

The study was approved by the HSL-PUCRS Scientific and Ethics Committee and is in compliance with the Brazilian regulatory guidelines for research involving human beings (National Health Council Resolution no. 466/12). All participants gave written informed consent.

The HSL-PUCRS smoking cessation program is a 12-month program and is representative of the daily clinical practice in smoking cessation treatment in Brazil. The physicians involved in the study were responsible for allocating the patients to each of the pharmacological treatment arms of the study: no pharmacological treatment, bupropion, nortriptyline, nicotine replacement therapy, and varenicline. To that end, the physicians considered the level of nicotine dependence, as determined with the Fagerström Test for Nicotine Dependence (FTND); tolerance to drugs in any previous smoking cessation treatments; patient preference for a given drug; and the financial ability of the patient to acquire the medication proposed, given that patients did not receive the medications for free. All patients received the same regimen of counseling. The program consisted of an initial medical interview, in which the patient completed a standardized questionnaire on smoking history and the level of motivation to quit. The physician then augmented the records with data regarding the general medical history, physical examination findings, baseline body weight, respiratory symptoms, and use of medications for the treatment of comorbidities. The level of nicotine dependence was then assessed with the FTND, which classifies it as low (FTND score ≤ 3), medium (FTND score of 4-7), or high (FTND score ≥ 8).[@B20] The concentration of exhaled carbon monoxide (eCO) was measured with a portable monoximeter (MicroCO; Micro Medical Limited, Rochester, England). Finally, the patient, the physician, and a nurse collectively agreed upon a quit day, typically scheduled for 8-9 days after the initial assessment. During the first three months of treatment, the patients attended individual treatment sessions, 15 days apart, all conducted by the same physician. After this initial period, the patients returned once a month until completing 12 months of abstinence. At all visits, the patients reported on their smoking habits and the eCO level was determined in order to confirm the smoking status. There were also visits with a trained nurse, specifically related to preventing weight change and developing strategies to cope with this problem. Withdrawal symptoms were also fully discussed in all sessions. The last follow-up visit was at 12 months of continuous abstinence, at which point the final weight was recorded. Body weight was always determined with the same scale (Filizola eletrônica digital; Industria Filizola, São Paulo, Brazil), calibrated as recommended by the manufacturer.

Successful treatment was defined as continuous abstinence (eCO \< 10 ppm at all visits). Subjects who discontinued treatment or were lost to follow-up were classified as cases of treatment failure and were not included in the analysis. Any patient who did not attend a scheduled appointment received a phone call from the outpatient clinic, as a routine procedure.

For assessing outcomes, we stratified the patients into two groups, according to changes in body weight: NoChange (weight unchanged or variation of no more than 5% in relation to the baseline weight); and Change (weight gain of more than 5%). Variations in body weight greater than 5% were considered clinically relevant.[@B19]

We described continuous variables as means ± standard deviations when the data distribution was normal and as medians and interquartile ranges when it was not. We described categorical variables as absolute and relative frequencies. We used the Student's t-test to compare means and the nonparametric Mann-Whitney test to compare medians. For categorical data comparisons, we used the chi-square test or Fisher's exact test.

To evaluate weight change during the follow-up period, we used a Poisson regression model with a robust standard error to estimate relative risk, calculating the corresponding 95% confidence intervals and adjusting for several potential confounders. In addition, to determine the magnitude of the impact that smoking cessation had on weight gain, we calculated the NNH and the corresponding 95% confidence interval. The level of significance was set at p \< 0.05. Data were analyzed with the SPSS Statistics software package, version 21.0 (IBM Corp., Armonk, NY, USA).

RESULTS
=======

We screened 450 smokers, of whom 102 were excluded ([Figure 1](#f1){ref-type="fig"}). Therefore, the final study sample comprised 348 patients, 161 (46.3%) of whom were abstinent throughout the 12-month follow-up period ([Figure 1](#f1){ref-type="fig"}).

Figure 1Flowchart of patients included in the study.

[Table 1](#t1){ref-type="table"} shows the characteristics of the patients evaluated, by outcome (success vs. failure in quitting smoking) and weight-change group (NoChange vs. Change). To maintain the numbers of patients in both groups, we used a cut-off age of 50 years, rather than the traditional 60 years. The cut-off age of 50 years has been used previously.[@B21] Among the 161 patients in whom the treatment was successful, 104 (64.6%) were in the NoChange group and 57 (35.4%) were in the Change group. Among the 187 patients in whom the treatment failed, 172 (92.0%) were in the NoChange group and 15 (8.0%) were in the Change group.

Table 1Demographic characteristics of the sample, by treatment outcome and weight-change group.^a^VariableTreatment successTreatment failure(n = 161)(n = 187)NoChangeChangepNoChangeChangep(n = 104)(n = 57)(n = 172)(n = 15)Female gender70 (67.3)41 (71.9)0.596121 (70.3)13 (86.7)0.239\< 50 years of age73 (70.2)31 (54.4)0.058112 (65.1)4 (26.7)0.050≥ 11 years of schooling9 (9.1)3 (5.3)0.53818 (10.7)0 (0.0)0.367Pack-years36 \[20-50\]35 \[26-57\]0.48243 \[28-60\]40 \[25-66\]0.964Treatment0.5060.669Counseling only8 (7.7)4 (7.0)54 (51.4)3 (20.0)Counseling + BUP78 (75.0)38 (66.7)85 (49.4)8 (53.3)Counseling + NRT4 (3.8)3 (5.3)12 (7.0)2 (13.3)Counseling + NOR5 (4.8)7 (12.3)17 (9.9)2 (13.3)Counseling + VAR9 (8.7)5 (8.8)4 (2.3)0 (0.0)Nicotine dependence level (FTND)0.3240.246Low33 (31.7)13 (22.8)45 (26.2)1 (6.7)Moderate48 (46.2)26 (45.6)81 (47.1)9 (60.0)High23 (22.1)18 (31.6)46 (26.7)5 (33.3)Baseline weight, kg71.6 ± 15.166.3 ± 11.30.02268.4 ± 15.366.9 ± 13.20.725Final weight, kg72.5 ± 15.072.0 ± 12.10.84268.1 ± 15.471.5 ± 13.60.410Baseline BMI, kg/m^2^26.9 ± 5.525.7 ± 4.40.17226.6 ± 5.826.8 ± 3.90.908Final BMI, kg/m^2^27.3 ± 5.527.9 ± 4.60.51826.5 ± 5.828.6 ± 4.00.196Delta BMI, kg/m^2^0.39 ± 0.572.21 ± 0.79\<0.001−0.11 ± 0.651.85 ± 0.65\<0.001[^1]

Among the patients in whom the treatment was successful, the baseline body weight was higher in the NoChange group patients than in the Change group patients, there being, as expected, less weight gain in the former group (p \< 0.001 for both). In general, there was a weak correlation between being younger and being in the NoChange group (p = 0.058). Among the patients in whom the treatment failed, those in the NoChange group were significantly younger than were those in the Change group, as well as showing significantly less weight gain (p = 0.05 for both). We found no significant differences between the two groups regarding any of the other characteristics evaluated. As can be seen in [Table 2](#t2){ref-type="table"}, the patients were also grouped into seven categories, according to the percent weight change in relation to the baseline weight. [Table 2](#t2){ref-type="table"} also shows the distribution of the percent weight change from the baseline weight by outcome. We detected significant differences between the two outcomes only for categories 3, 4, 6, and 7.

Table 2Distribution by weight-change category and treatment outcome among patients undergoing smoking cessation treatment (N = 348).Category% change from baseline weightSuccessFailure(n = 161)(n = 187)n (%)n (%)1-weight loss≥ 10.0000 (0)1 (0.5)2-weight loss9.990 to 5.0001 (0.6)7 (3.7)3-weight loss4.990 to 0.00124 (14.9)72 (38.5)\*4-weight maintained09 (5.6)23 (12.3)\*5-weight gain\> 0.001 to 4.99070 (43.5)69 (36.9)6-weight gain5.000 to 9.99039 (24.2)13 (7.0)\*7-weight gain≥ 10.00018 (11.2)2 (1.1)\*[^2]

[Table 3](#t3){ref-type="table"} demonstrates the risk factors for Change group patients, in univariate analysis and multivariate Poisson regression (adjusted for gender, age, level of nicotine dependence, pharmacological treatment received, number of clinical visits attended, and baseline body weight). None of the factors evaluated were found to confer significant risk for or protection against a \> 5% weight gain in relation to the baseline weight. [Figure 2](#f2){ref-type="fig"} shows the risk and protective factors in a forest plot. The NNH for a \> 5% weight gain in relation to the baseline weight was 3.6 (95% CI: 2.8-5.4).

Table 3Univariate analysis and multivariate Poisson regression of risk factors associated with a weight gain of more than 5% in relation to the baseline weight among the patients in whom the treatment was successful (n = 161).VariableCrude RR (95% CI)pAdjusted RR\* (95% CI)pFemale gender1.15 (0.65-2.06)0.631.15 (0.63-2.11)0.64\< 50 years of age1.53 (0.91-2.58)0.111.63 (0.94-2.83)0.081≥ 11 years of schooling0.67 (0.21-2.13)0.490.72 (0.22-2.36)0.59Pack-years1.00 (0.99-1.01)0.661.01 (0.99-1.02)0.41Comorbidities1.15 (0.64-2.08)0.631.24 (0.66-2.32)0.51TreatmentCounseling11Counseling + BUP0.98 (0.35-2.75)0.970.93 (0.33-2.62)0.89Counseling + NRT1.29 (0.29-5.75)0.741.36 (0.30-6.18)0.69Counseling + NOR1.75 (0.51-5.98)0.371.25 (0.36-4.37)0.73Counseling + VAR1.07 (0.29-3.99)0.920.99 (0.26-3.71)0.98Nicotine dependence (FTND)Low11Moderate1.24 (0.64-2.42)0.521.15 (0.58-2.28)0.69High1.53 (0.76-3.17)0.231.49 (0.71-3.13)0.29Baseline weight0.98 (0.96-1.00)0.060.98 (0.96-1.01)0.12Baseline BMI, kg/m^2^0.97 (0.91-1.03)0.270.98 (0.92-1.04)0.41\< 241125-300.77 (0.43-1.41)0.400.97 (0.51-1.84)0.93\> 300.66 (0.30-1.47)0.310.70 (0.31-1.61)0.40Medical visits attended (n)1.08 (1.01-1.15)0.021.05 (0.88-1.26)0.56[^3]

Figure 2Forest plot of risk and protective factors for significant weight gain, adjusted for gender, age, and level of nicotine dependence (Fagerström Test of Nicotine Dependence), treatment, and follow-up. RR: relative risk; BUP: bupropion; CBT: cognitive behavioral therapy; NRT: nicotine replacement therapy; NOR: nortriptyline; VAR: varenicline; and BMI: body mass index. \*Logistic regression model adjusted for gender, age, level of nicotine dependence (Fagerström Test for Nicotine Dependence score), treatment, and follow-up.

DISCUSSION
==========

In this study, the majority of the patients who achieved continuous smoking abstinence after quitting smoking had no significant weight changes or maintained their initial weight. Although many smokers gain weight after quitting smoking, the weight gain is usually minimal,[@B5] ^,^ [@B12] ^,^ [@B22] as we found in our sample. Therefore, the widespread notion in the lay population and among some health professionals that smoking cessation is necessarily associated with weight gain is not entirely true.

Aubin et al.[@B12] found that quitting smoking was associated with a mean weight gain of 4.7 kg at 12 months after smoking cessation, 13% of the abstinent smokers having gained more than 10 kg. However, a significant proportion of the former smokers evaluated in that study actually lost weight. Tian et al.[@B23] assessed data from 63,403 individuals who quit smoking, evaluating 388,432 current smokers as a control group. The former smokers had a mean weight gain of 4.10 kg (95% CI: 2.69-5.51), which was significantly greater than that observed in the current smokers (p \< 0.001).

Of the 187 patients in whom the treatment failed in the present study, 172 (92.0%) patients had a weight change \< 5% in relation to the baseline weight The lack of relevant changes in this group might be related to the attempt to quit smoking or to the natural weight variation of the subjects during the study period.

Our findings are consistent with those of other studies in the literature. Aubin et al.[@B12] showed that the majority (84%) of their abstinent patients gained weight, whereas 16% lost weight. In the present study, those proportions were 78.9% and 15.5%, respectively, and 5.6% of our patients maintained their baseline weight.

It is known that some of the drugs prescribed for smoking cessation can promote weight changes. Bupropion is widely used for slimming as well as for smoking cessation.[@B19] Although nortriptyline is associated with weight gain when used to treat depression,[@B24] its specific role in weight changes when used in smoking cessation treatment has not been fully tested. However, we found no significant differences among the pharmacological treatment arms in terms of weight changes. Aubin et al.[@B12] reported similar findings in a study comparing the use of nicotine replacement therapy, bupropion, varenicline, and no pharmacotherapy.

The factors that have been associated with weight gain after smoking cessation include male gender, a higher level of nicotine dependence, and advanced age.[@B22] There have also been studies showing that being \< 55 years of age and having a lower SES are significant risk factors for weight gain after smoking cessation.[@B25] Discrepancies across studies are likely related to differences in the length of the follow-up period.

On average, smokers weigh less than do nonsmokers. The proportion of smokers who are overweight or obese in a given population is reflective of the dietary habits in the respective country or region. Many smokers are already overweight or even have class III obesity when they attempt to quit smoking. Smoking is especially common among individuals who are preparing to undergo bariatric procedures. In a previous study conducted at our facility,[@B7] the relationship between class III obesity and smoking was evaluated, and patients with class III obesity were found to be two times more likely to be a smoker than were those with lower BMIs.[@B7] Those findings might be a consequence of various overlapping risk behaviors, because smokers are typically less physically active and prefer a less healthy diet, as well as consuming greater quantities of alcohol, in comparison with their non-smoking counterparts. In a subsequent study, involving 536 individuals with class III obesity, smoking was found to correlate positively with BMI, waist circumference, and percentage of body fat among the male patients with class III obesity.[@B9]

Although our findings confirm previously published results, our study adds some innovative information. To our knowledge, this is the first paper to use NNH calculation, a simple technique, to determine the number of treated patients needed in order to detect one with a significant weight change. The fact that we calculated an NNH of 3.6 means that for every 3.6 people treated, only one will show a weight gain of more than 5%, whereas 2.4 will maintain their baseline weight or even lose a small proportion. The dissemination of our findings could be useful for encouraging smokers to quit. Patients should be informed that weight gain is not a significant problem in the majority of the cases.[@B24] The benefits of quitting smoking outweigh any potential risks related to weight gain. Patients should also be informed that systemic arterial hypertension and type 2 diabetes mellitus, as collateral effects of weight gain-often mentioned by patients as major concerns-are uncommon, and that the benefits of quitting by far offset the consequences of weight gain related to smoking cessation.[@B26] ^,^ [@B27] Nevertheless, in our sample, 11% of the patients in whom treatment success was achieved showed weight gains that could be harmful to their health (more than 10% in relation to the baseline weight). Of the patients in whom the treatment failed, only 1.1% showed such weight gains.

This study has a number of strengths. Because we employed a real-world prospective cohort design, our findings reflect the routine scenario of smoking cessation treatment at outpatient clinics in Brazil. Our sample is representative of the patients treated via the Brazilian Unified Health Care System. Another positive point is that we managed to perform biochemical verification of smoking withdrawal in all cases, despite the long follow-up period. All patients had to purchase their own medication, which could be an indicator of good adherence to the treatment and of a strong motivation to try to complete the task of quitting smoking. Another strength is that we expressed weight change as a percentage of the baseline weight, rather than as an absolute value. This innovative strategy was implemented in order to prevent erroneous interpretations. To avoid measurement errors,[@B14] ^,^ [@B28] body weights were verified by a health care professional.

Our study has some limitations. The high proportion of patients treated with bupropion could have introduced a bias. However, after adjusting for several factors, we found that treatment with bupropion had no significant influence on the results. In terms of the treatment received, the patients in whom treatment success was achieved were comparable to those in whom the treatment failed. However, when we stratified the patients by weight-change group (NoChange and Change), we detected differences in the two groups that were controlled by the multivariate Poisson regression. Another limitation is that we did not evaluate possible modifications in physical activity or lifestyle. The patients might have gained weight because of lifestyle changes, such as becoming more sedentary, or might have lost weight because they started engaging in regular physical activity. In addition, patients who exercised could have increased their muscle mass, with a consequent increase in weight, which could be better evaluated by bioimpedance. Unfortunately, when we started this study, we did not have access to the equipment necessary in order to assess body composition or to determine the proportional distribution of lean and fat mass in each body segment. In the multivariate analysis, we adjusted for the possible bias of using drugs that can affect the appetite. Because this was a real-world study, the patients were not randomized to the various treatments, which could represent a bias related to patients selecting the medications on the basis of price. However, that reflects what happens in daily practice: patients do not receive medication for free. Because our findings are in keeping with those of other studies in the literature,[@B27] ^,^ [@B29] we are confident that these limitations did not have a significant influence on our results.

The idea that weight gain after smoking cessation can be insignificant when specific measures for weight control are taken should be widely disseminated. Health care professionals, especially those working at primary health care clinics or smoking cessation treatment centers, should use this information as a tool to emphasize to patients that, although there truly is a possibility of weight gain during smoking cessation treatment, such weight gain occurring in a non-negligible proportion of patients, a larger proportion of patients retain their baseline weight or even lose weight. Health care professionals should further explain that weight changes will not be a major problem if certain precautions are taken.[@B27] ^,^ [@B30] ^,^ [@B31] They should transmit to the smoker the idea that it is possible to quit smoking without a great risk of weight gain or of the specific comorbidities usually associated with obesity, such as systemic arterial hypertension and diabetes mellitus.[@B29] This strategy could help motivated smokers overcome barriers and encourage them to give up the habit. It could also be useful in addressing undecided smokers who are concerned about possible weight gain.

Study carried out in the Ambulatório de Auxílio ao Abandono do Tabagismo, Hospital São Lucas, Faculdade de Medicina, Pontifícia Universidade Católica do Rio Grande do Sul - PUCRS - Porto Alegre (RS) Brasil.
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[^1]: NoChange: weight unchanged or variation of no more than 5% in relation to the baseline weight; Change: weight gain of more than 5%; BUP: bupropion; NRT: nicotine replacement therapy; NOR: nortriptyline; VAR: varenicline; FTND: Fagerström Test for Nicotine Dependence (score); and BMI: body mass index. ^a^Data are presented as mean ± SD, median \[interquartile range\], or n (%).

[^2]: \*p ≤ 0.05.

[^3]: RR: relative risk; FTND: Fagerström Test for Nicotine Dependence (score); BUP: bupropion; NRT: nicotine replacement therapy; NOR: nortriptyline; VAR: varenicline; and BMI: body mass index. \*Adjusted for gender, age, level of nicotine dependence (FTND score), treatment, number of visits attended, and baseline weight.
